Epilepsy Drug Offers Hope for Severe Snorers

A repurposed epilepsy medication, Sultiame, is emerging as a potential treatment for obstructive sleep apnea (OSA), a condition affecting nearly a billion people globally. This drug, used as an anticonvulsant since the 1950s, has demonstrated a significant reduction in OSA symptoms during recent trials.

Researchers observed that patients taking Sultiame experienced up to 47 percent fewer breathing interruptions during sleep. These positive results, published in The Lancet, also indicated improved overnight oxygen levels and reduced daytime sleepiness for participants. These findings represent a potential breakthrough in managing OSA.

Obstructive sleep apnea causes throat walls to relax and narrow or close during sleep, leading to pauses in breathing and loud snoring. While current treatments include lifestyle changes and CPAP masks, many patients find these methods cumbersome or abandon them. The study's success suggests a viable pharmacological alternative.

Professor Jan Hedner, a study co-author, described the findings as "a breakthrough," highlighting the potential for pharmacological intervention in sleep apnea. Larger, long-term studies are planned to confirm the treatment's sustained effect and safety for wider patient populations.